Abstract
Much progress has been made in the diagnosis and treatment of Hodgkin's lymphoma, which has become a highly curable malignancy. However, prolonged survival makes clinicians pay more attention to long-term toxicities of treatment. Consequently, individualized treatment based on disease stage and risk factors is a research hotspot at present. This article reviews recent advances in the individualized treatment of early-stage classical Hodgkin's lymphoma. Key words: Hodgkin disease/radiotherapy; Hodgkin disease/chemotherapy; Risk assessment; Tomography, positron-emission
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
